Adverse currency movements and the integration of Sauflon Pharmaceuticals, the U.K.-based contact lens company, acquired last August, led Cooper Companies to report worse results than previously expected for the fourth quarter ended on Oct. 31, especially for its CooperVision (CVI) subsidiary.
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.